相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combinatorial use of bone morphogenetic protein 6, noggin and SOST significantly predicts cancer progression
Hiu-Fung Yuen et al.
CANCER SCIENCE (2012)
Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
Hiu-Fung Yuen et al.
CLINICAL CANCER RESEARCH (2012)
The Role of Pea3 Group Transcription Factors in Esophageal Squamous Cell Carcinoma
Hiu-Fung Yuen et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer
Ivan S. Donev et al.
CLINICAL CANCER RESEARCH (2011)
Dual-specific Phosphatase-6 (Dusp6) and ERK Mediate AMPA Receptor-induced Oligodendrocyte Death
Maria Domercq et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+CML stem/progenitor cells
F. Pellicano et al.
LEUKEMIA (2011)
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
V. Serra et al.
ONCOGENE (2011)
Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic
Paul Workman et al.
CANCER RESEARCH (2010)
Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells
Jun Sunayama et al.
STEM CELLS (2010)
Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
Olga K. Mirzoeva et al.
CANCER RESEARCH (2009)
Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma
Sandrine Guillard et al.
CELL CYCLE (2009)
Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma
Da-Liang Ou et al.
CLINICAL CANCER RESEARCH (2009)
Negative and Positive Regulation of MAPK Phosphatase 3 Controls Platelet-derived Growth Factor-induced Erk Activation
Aleksandra Jurek et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair
M-A Westhoff et al.
ONCOGENE (2009)
Class IPI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity
Remko Prevo et al.
CANCER RESEARCH (2008)
Cotargeting survival signaling pathways in cancer (vol 118 pg 3003, 2008)
Steven Grant
JOURNAL OF CLINICAL INVESTIGATION (2008)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
Post-translational regulation of the ERK phosphatase DUSP6/MKP3 by the mTOR pathway
O. Bermudez et al.
ONCOGENE (2008)
Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations
Dingxie Liu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases
Florence I. Raynaud et al.
CANCER RESEARCH (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Synthesis and biological evaluation of pyrido[3′,2':4,5]furo [3,2-d]pyrimidine derivatives as novel PI3 kinase p110α inhibitors
Masahiko Hayakawa et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5
Alex von Kriegsheim et al.
NATURE CELL BIOLOGY (2006)
Negative regulation of ERK activity by VRK3-mediated activation of VHR phosphatase
Tae-Hong Kang et al.
NATURE CELL BIOLOGY (2006)
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
DD Sarbassov et al.
MOLECULAR CELL (2006)
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition
SY Sun et al.
CANCER RESEARCH (2005)
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
PM LoRusso et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040
YL Wang et al.
NEOPLASIA (2005)
Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants
HM McDaid et al.
CANCER RESEARCH (2005)
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
J Rinehart et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cl-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK)
LF Allen et al.
SEMINARS IN ONCOLOGY (2003)
Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway
M Jost et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways
GH Xiao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Development of anticancer drugs targeting the MAP kinase pathway
JS Sebolt-Leopold
ONCOGENE (2000)
分享论文
